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OBJECTIVES This study was designed to determine whether nesiritide, administered for acute decompen-
sated congestive heart failure (CHF), affects healthcare costs by hospital length of stay (LOS),
readmissions and short-term mortality, compared to dobutamine.
BACKGROUND Dobutamine is a commonly used inotropic treatment for CHF. Although dobutamine may
have favorable hemodynamic and symptomatic effects, its use may be associated with side
effects such as tachycardia, cardiac arrhythmias and myocardial ischemia. Nesiritide (B-type
natriuretic peptide) is a new intravenous (IV) drug that produces hemodynamic and
symptomatic improvement through balanced vasodilatory effects, neurohormonal suppression
and enhanced natriuresis and diuresis.
METHODS From an open-label randomized study of nesiritide versus standard care (SC) in patients with
CHF requiring hospitalization, we compared short-term outcome data from patients given
nesiritide (0.015 or 0.03 g/kg per min) with a subgroup of SC patients given dobutamine.
A total of 261 patients are included in this analysis.
RESULTS Compared to dobutamine, both nesiritide doses were administered for a shorter total duration
(p 0.001), and the total duration of all IV vasoactive therapy (including study drug) was also
shorter (p  0.012). Although there was no difference in LOS, there was a trend toward
decreased readmissions in the two nesiritide groups (8% and 11%, respectively, vs. 20% in the
dobutamine group). Six-month mortality was lower in the nesiritide groups.
CONCLUSIONS Treatment of decompensated CHF with nesiritide may lead to lower healthcare costs and
reduced mortality compared to treatment with dobutamine. (J Am Coll Cardiol 2002;39:
798–803) © 2002 by the American College of Cardiology Foundation
Heart failure is a healthcare problem of enormous propor-
tion. It has recently been reported to be the primary
diagnosis in 872,000 hospital admissions in the U.S. and the
secondary diagnosis in an additional 1.8 million admissions
(1,2). Dobutamine is a widely used inotropic therapy for
decompensated heart failure. Although dobutamine can
cause early hemodynamic and symptomatic benefits, its use
is limited by potentially serious side effects such as tachy-
cardia, hypotension, myocardial ischemia and cardiac ar-
rhythmias. Furthermore, increased mortality associated with
chronic administration of oral inotropic agents has raised
concern over the safety of these agents, even when used
short term (3–6).
Nesiritide, an intravenous (IV) form of human B-type
natriuretic peptide (marketed as Natrecor, Scios, Inc.,
Sunnyvale, California), is the first in a new pharmacologic
class of drug for treatment of decompensated congestive
heart failure (CHF). Given parenterally, nesiritide causes
cyclic guanosine monophosphate-mediated balanced arterial
and venous dilation and may lead to neurohormonal sup-
pression, natriuresis and diuresis (7–9). Recent evaluation of
nesiritide in the treatment of acute decompensated CHF
has demonstrated significant symptom improvement, in
association with decreased preload and afterload and in-
creased cardiac output, without a proarrhythmic effect (7,8).
To determine if treatment with nesiritide in hospitalized
patients with decompensated CHF affected healthcare uti-
lization or longer term outcomes compared to dobutamine,
we examined length of stay (LOS), readmissions and
six-month mortality data from a subgroup analysis prospec-
tive, randomized active-control trial.
METHODS
Eligible patients were at least 18 years of age with a history
of chronic heart failure and were admitted to an acute care
hospital for symptomatic, decompensated heart failure re-
quiring inpatient IV vasoactive treatment. Patients were
excluded if they had prior treatment for 4 h with an IV
vasoactive agent for this episode of heart failure, a myocar-
dial infarction within 48 h before entry into study, valvular
stenosis, hypertrophic obstructive cardiomyopathy, constric-
tive pericarditis, primary pulmonary hypertension, acute
myocarditis, complex congenital heart disease, shock, sys-
tolic blood pressure (BP) 90 mm Hg or significant
hemodynamic instability requiring immediate inotropic or
pressor support. All patients gave informed consent, and
each institution’s local board for the protection of human
subjects approved the study protocol. Prospectively defined
end points included duration of IV vasoactive therapy,
hospital LOS, hospital readmissions (both all-cause and due
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to CHF) through day 21 and the need for additional
vasoactive agents. Six-month mortality data were collected
retrospectively.
In this multicenter open-label (double-blind to nesiritide
dose) study, patients were randomized to three treatment
groups in a 1:1:1 ratio: 1) standard care (SC), an
investigator-chosen single IV vasoactive agent; 2) nesiritide
0.015 g/kg per min infusion, preceded by a 0.3 g/kg IV
bolus; or 3) nesiritide 0.030 g/kg per min infusion,
preceded by a 0.6 g/kg IV bolus (Fig. 1). Standard care
vasoactive agents included dobutamine, milrinone, nitro-
glycerin or nitroprusside. Investigators could add a second
IV vasoactive agent (or substitute a new agent for the first
choice) at their discretion, but nesiritide could not be given
as the second agent to SC patients. The addition of a second
IV vasodilator to nesiritide therapy was not permitted, but
the former could be substituted for the latter. In all groups,
dose changes and total duration of therapy were left to
investigator’s discretion.
Statistical methods. This paper summarizes the compari-
sons of a subgroup of patients randomized to SC who
received dobutamine with patients randomized to two doses
of nesiritide. Descriptive statistics were provided for gender,
age, ethnicity, New York Heart Association (NYHA) clas-
sification, primary etiology of CHF and cardiac history.
Summaries of concomitant medication usage, treatment
information and healthcare utilization were provided for
each treatment group. Generally, continuous data were
analyzed by the omnibus F test followed by pairwise
contrasts, ordinal data by the Kruskal-Wallis test followed
by pairwise two-sample Wilcoxon tests and categorical data
by the generalized Fisher Exact test followed by pairwise
Fisher Exact test. Kaplan-Meier estimates of the six-month
mortality rate were also provided for each group. Log-rank
test was used to assess the differences of six-month mortality
between the dobutamine subgroup and each nesiritide dose
group. Data are expressed as mean  standard deviation
unless otherwise noted. A p value 0.05 was considered
statistically significant. No pairwise multiple comparison
adjustments are included.
RESULTS
Between January 1997 and July 1997, 305 patients were
enrolled into the study from 46 U.S. study sites. One
hundred two patients were randomized to SC. Of these, 58
(57%) patients received dobutamine as the first-choice
SC agent. One hundred three patients received nesiritide
0.015 g/kg per min and 100 patients received nesiritide
0.030 g/kg per min. Baseline demographics and medical
history information is summarized in Table 1. The study
population was elderly (mean age 65  13 years), 32% were
women and 31% were minorities. As intended, 92% of
patients had a chronic history of NYHA class III or IV
CHF before admission. Fifty-four percent had a history of
a previous myocardial infarction (MI), 40% had a history of
atrial fibrillation and 24% had a history of ventricular
tachycardia (VT) (21% nonsustained and 8% sustained). In
general, baseline characteristics (Table 1) and baseline
hemodynamics (Table 2) among the groups were well
balanced, with the following exceptions: more dobutamine
patients had a history of previous MI and ischemia as the
primary etiology of CHF, fewer nesiritide 0.015 g/kg per
min patients were white or had a history of sudden death,
and more nesiritide 0.030 g/kg per min patients had a
history of sustained VT. Before study drug administration,
there were no significant differences in the chronic use of
diuretics (83%), digoxin (59%), angiotensin-converting en-
zyme inhibitors (60%) or beta-blockers (10%).
Median duration of study drug was significantly shorter
in the nesiritide dose groups than in the dobutamine group
by 25 h (nesiritide 0.015 g/kg per min) and 39 h (nesiritide
0.030 g/kg per min) (Table 3). In addition, compared to
the dobutamine group, patients randomized to nesiritide
received one less day of treatment with all IV vasoactive
drug therapies combined (overall p  0.016, pairwise p 
0.05) (Table 3). Dobutamine-treated patients were more
likely to undergo both dose increases and dose decreases,
whereas nesiritide was more likely to be administered as a
fixed-dose infusion (Table 3). The use of combination
therapy with other IV vasoactive agents during nesiritide
therapy was similar to that observed with dobutamine
(overall p 0.589) (Table 3). A small number of patients (9
in the low-dose and 12 in the high-dose nesiritide groups)
were placed on a second IV agent after discontinuing
nesiritide. Compared with nesiritide-treated patients, sig-
nificantly greater numbers of patients treated with dobut-
amine received a phosphodiesterase inhibitor, dopamine,
non-dopamine vasopressors, diuretics or digoxin during
treatment with study drug (Table 4). In nesiritide-treated
Abbreviations and Acronyms
BP  blood pressure
CHF  congestive heart failure
IV  intravenous
LOS  length of stay
MI  myocardial infarction
NYHA  New York Heart Association
SC  standard care
VT  ventricular tachycardia
Figure 1. Study schema. IV  intravenous.
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patients who required concomitant IV vasoactive therapy,
dobutamine was the most common agent used (Table 4).
Overall hospital LOS was no different among the groups
(Table 5). The percentage of nesiritide-treated patients
(both doses) readmitted for CHF within 21 days was
approximately 69% lower than observed in patients receiv-
ing dobutamine (p  0.06 for each nesiritide dose group vs.
dobutamine). All-cause readmissions were 60% lower in
patients treated with nesiritide 0.015 g/kg per min (p 
0.05 vs. dobutamine) and 45% lower in the 0.030 g/kg per
min group (p  0.1 vs. dobutamine, Table 5). Systolic BP
at 24 h was significantly reduced in the nesiritide-treated
groups compared with the dobutamine-treated group (Ta-
ble 2). Heart rate for all three groups remained essentially
the same after 24 h of treatment. Diastolic BP was signif-
icantly reduced from baseline in each nesiritide group, but
the changes were not significantly different from dobut-
amine.
Six-month mortality was lower in the 0.015 g/kg per
min nesiritide group compared with the dobutamine-
treated group. Six-month mortality in the 0.030 g/kg per
min nesiritide group was also lower than that observed with
dobutamine (Table 5, Fig. 2).
Adverse events. The incidence of select cardiovascular
events reported during the first 24 h of dosing is summa-
rized in Table 6. During the first 24 h, the incidence of
symptomatic and asymptomatic hypotension was higher in
the nesiritide treatment groups compared to dobutamine.
The events were easily managed with either dose reduction
or discontinuation. Bradycardia tended to be more common
Table 1. Demographics and Baseline Medical History
Characteristics
All Subjects
(n  261)
Dobutamine
Subgroup
(n  58)
Nesiritide (g/kg per min)
Overall
p Value
0.015
(n  103)
0.030
(n  100)
Age* 65  13 64  14 63  14 65  12 0.520†
Race
White 179 (69%) 47 (81%) 61 (59%) 71 (71%)
Black 57 (22%) 9 (16%) 28 (27%) 20 (20%) 0.132‡
Hispanic 21 (8%) 2 (3%) 11 (11%) 8 (8%)
Other 4 (2%) 0 (0%) 3 (3%) 1 (1%)
Gender: Male 178 (68%) 44 (76%) 67 (65%) 67 (67%) 0.361‡
NYHA
I, II 22 (8%) 4 (7%) 6 (6%) 12 (12%) 0.548§
III 139 (53%) 30 (52%) 57 (55%) 52 (52%)
IV 100 (38%) 24 (41%) 40 (39%) 36 (36%)
CHF etiology
Ischemia 146 (56%) 39 (67%) 53 (51%) 54 (54%)
IDC 56 (21%) 11 (19%) 27 (26%) 18 (18%) 0.029‡
Hypertensive 21 (8%) 0 (0%) 12 (12%) 9 (9%)
Other 38 (15%) 8 (14%) 11 (11%) 19 (19%)
Previous MI 140 (54%) 40 (69%) 51 (50%) 49 (49%) 0.030‡
Sudden death 23 (9%) 7 (12%) 2 (2%) 14 (14%) 0.002‡
Atrial fibrillation 105 (40%) 28 (48%) 40 (39%) 37 (37%) 0.357‡
Nonsustained VT 55 (21%) 15 (26%) 17 (17%) 23 (23%) 0.304‡
Sustained VT/VF 22 (8%) 4 (7%) 3 (3%) 15 (15%) 0.008‡
*Mean  standard deviation; †Omnibus F test; ‡Fisher Exact test, two-tailed; §Kruskall-Wallis test.
IDC  idiopathic dilated cardiomyopathy; MI  myocardial infarction; NYHA  New York Heart Association; VF 
ventricular fibrillation; VT  ventricular tachycardia.
Table 2. Baseline Blood Pressure and Heart Rate, and Change From Baseline at 24 h
(Mean  SD)
Parameter
Dobutamine
Subgroup
(n  58)
Nesiritide (g/kg per min)
Overall
p Value*
0.015
(n  103)
0.030
(n  100)
Systolic BP
Baseline 118.9  19.84 126.8  24.95 123.9  25.86 0.154
Change from baseline 3.5  17.23 14.1  18.96† 14.8  21.30† 0.002
Diastolic BP
Baseline 69.9  13.91 70.8  14.77 68.4  15.14 0.507
Change from baseline 5.2  14.25 8.1  12.50 8.2  13.09 0.353
Heart rate
Baseline 85.6  16.38 83.2  18.21 83.8  14.78 0.687
Change from baseline 0.1  11.89 0.3  13.55 1.0  12.24 0.906
*Fisher Exact test, two-tailed; †p  0.05, relative to dobutamine, analysis of variance.
BP  blood pressure.
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in the nesiritide-treated groups compared with the
dobutamine-treated group, although the difference was not
statistically significant (overall p  0.258).
DISCUSSION
Use of nesiritide in the treatment of CHF. The results of
this large multicenter trial demonstrate that, in comparison
to dobutamine, the use of nesiritide for the initial manage-
ment of acute decompensated CHF was associated with a
shorter treatment course with IV vasoactive therapy, the
use of fewer additional parenteral agents and reduced
hospital readmission rates. In patients receiving nesiritide
0.015 g/kg per min, there was a significantly lower
six-month mortality rate compared with patients receiving
dobutamine.
Nesiritide versus dobutamine. Readmission for decom-
pensated CHF is a common event for patients with ad-
vanced heart failure and can be affected by the adequacy of
initial hospital care (10). The present study suggests that
nesiritide may be more effective than dobutamine (shorter
treatment course, fewer additional agents) and that these
short-term benefits may have longer lived effects (reduced
CHF rehospitalization and reduction in mortality). Al-
though the exact mechanisms for the differential effects of
nesiritide in this study are not entirely clear, they may
include favorable neurohormonal changes and enhanced
diuretic effect with nesiritide and/or unfavorable effects of
dobutamine such as increased myocardial oxygen consump-
tion, direct myocardial toxicity or arrhythmogenesis.
Pharmacoeconomic considerations. Decompensated
CHF is a major cause of hospital admissions in the U.S. and
is the leading cause of acute care hospital admissions for
patients over the age of 65 years (1,2). Early improvement of
symptoms due to hemodynamic compensation, diuresis and
natriuresis is often achieved with parenteral therapy, fol-
lowed by the transition to an appropriate outpatient regi-
men. Achieving these goals rapidly and economically is
essential for improvement of patient care and control of the
financial burden from this condition. Overall cost of care is
a complex variable that is based not only on the cost of
therapeutic agents and procedures, but also on resource
utilization (level of care, treatment of serious complications,
LOS, readmission rates), which in turn is affected by the
efficacy and safety profiles of the therapeutics used.
Table 3. Treatment Information
Characteristics
Dobutamine
Subgroup
(n  58)
Nesiritide (g/kg per min)
Overall
p Value
0.015
(n  103)
0.030
(n  100)
Duration of therapy (h)*
Study drug 65 40† 26†  0.001‡
All IV vasoactive therapies 65 42† 41† 0.016‡
Dose modification
No change 23 (40%) 73 (71%) 57 (57%) 0.001§
Increase above initial dose 16 (28%) 11 (11%) 10 (10%) 0.008§
Other dose increases 12 (21%) 13 (13%) 29 (29%) 0.015§
Decrease 29 (50%) 17 (17%) 18 (18%)  0.001§
Study drug as sole IV agent 53 (91%) 86 (83%) 76 (76%) 0.049§
Combination IV therapy 5 (9%) 8 (8%) 12 (12%) 0.589§
*Median; †p  0.05, relative to dobutamine, Wilcoxon test; ‡Kruskal-Wallis test among all three groups; §Fisher Exact test,
two-tailed.
IV  intravenous.
Table 4. Concomitant Medications During Initial Study Drug Therapy (Number and Percent of
Subjects)
Medication
Dobutamine
Subgroup
(n  58)
Nesiritide (g/kg per min)
Overall
p Value*
0.015
(n  103)
0.030
(n  100)
IV vasoactive
Dobutamine — 5 (5%) 11 (11%) —
PDE inhibitor 4 (7%) 1 (1%) 0 (0%) 0.009
Nitroglycerin 1 (2%) 1 (1%) 1 (1%) 1.000
Nitroprusside 2 (3%) 2 (2%) 0 (0%) 0.169
Dopamine 6 (10%) 1 (1%) 2 (2%) 0.009
Pressors 2 (3%) 0 (0%) 0 (0%) 0.049
Diuretics 58 (100%) 84 (82%) 74 (74%)  0.001
Digoxin 49 (84%) 69 (67%) 63 (63%) 0.012
ACE inhibitors 39 (67%) 70 (68%) 54 (54%) 0.089
Beta-blockers 6 (10%) 9 (9%) 7 (7%) 0.745
*Fisher Exact test, two-tailed.
ACE  angiotensin-converting enzyme; IV  intravenous; PDE  phosphodiesterase.
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Study limitations. The results of the study are limited by
its open-label design, nonrandomized selection of therapies
used in the SC group by the investigators and the relatively
small number of patients in each subgroup. The
dobutamine-treated patients had a higher incidence of
ischemia and previous MI compared with the nesiritide-
treated patients. Therefore, the choice of dobutamine as the
SC agent by the investigator may have selected a sicker
patient population for this subgroup. More information
from a larger blinded study will be required to confirm the
results of this study. In addition, the lack of a placebo group
does not allow for the determination of whether the
different outcomes observed between the treatment groups
were due to a beneficial effect of nesiritide or a detrimental
effect of dobutamine. Finally, although the current recom-
mended dose of nesiritide is an infusion of 0.010 g/kg per
min (preceded by a 2 g/kg bolus), in this study nesiritide
was administered at doses one-and-a-half to three times
higher.
Conclusions. This study demonstrated that the use of
nesiritide was associated with a shorter treatment course, the
use of fewer additional parenteral agents, reduced rehospi-
talization rate and a significantly lower mortality rate at six
months (in the 0.015 g/kg per min dose group) when
compared to dobutamine. Thus, this study suggests that the
short-term clinical benefits of nesiritide, the first in the new
class of B-type natriuretic peptides for treatment of CHF,
may be associated with decreased healthcare utilization costs
Table 5. Healthcare Utilization and Mortality
Outcomes
Dobutamine
Subgroup
(n  58)
Nesiritide (g/kg per min)
Overall
p Value
0.015
(n  103)
0.030
(n  100)
Median length of stay (days) 4.5 5 5 0.411‡
Still hospitalized on day 21 4 (7%) 2 (2%) 4 (4%) 0.259§
All-cause readmission (by day 21) 11 (20%) 8 (8%)* 11 (11%) 0.085§
CHF readmission 7 (13%) 4 (4%)† 4 (4%)† 0.081§
Six-month mortality rate 18 (31%) 18 (18%)* 24 (24%) 0.123
Lost to follow-up at six months 0 (0%) 0 (0%) 2 (2%) —
*p  0.05 compared to dobutamine, pairwise contrast; †p  0.06 compared to dobutamine, pairwise contrast; ‡Kruskal-Wallis
test; §Fisher Exact test, two-tailed; Log-rank test.
CHF  congestive heart failure.
Figure 2. Kaplan-Meier estimate of mortality. Circles dobutamine (n 58); squares nesiritide 0.6 g/kg 0.030 g/kg per min (n 100); triangles
nesiritide 0.3 g/kg 0.015 g/kg per min (n  103).
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and improved long-term survival, compared to the com-
monly used inotropic agent, dobutamine.
PARTICIPATING INVESTIGATORS
The Nesiritide Study Group–Comparative Trial Investiga-
tors has been previously described (7).
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Table 6. Selected Cardiovascular Adverse Events During the First 24 h of Dosing (Number and
Percent of Subjects)
Adverse Event
Dobutamine
Subgroup
(n  58)
Nesiritide (g/kg per min)
Overall
p Value*
0.015
(n  103)
0.030
(n  100)
Symptomatic hypotension 3 (5%) 11 (11%) 17 (17%) 0.085
Asymptomatic hypotension 3 (5%) 15 (15%) 26 (26%) 0.002
Sustained VT 1 (2%) 0 (0%) 0 (0%) 0.222
Nonsustained VT 3 (5%) 10 (10%) 1 (1%) 0.015
Bradycardia 0 (0%) 5 (5%) 4 (4%) 0.258
Heart arrest 1 (2%) 0 (0%) 0 (0%) 0.222
*Fisher Exact test, two-tailed.
VT  ventricular tachycardia.
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